Ephedrine, Atropine Sulfate Continued Use In Analgesics Sought
This article was originally published in The Tan Sheet
Executive Summary
FDA reconsideration of its final rule barring continued use of ephedrine sulfate and atropine sulfate in OTC combination menstrual, internal muscle ache and back pain products is requested by Canton, Mass.-based Otis Clapp in a Sept. 29 letter. Published Aug. 24, the rule bans the ingredients from such uses based on a lack of efficacy data ("The Tan Sheet" Aug. 24, p. 7).